A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours

被引:0
作者
D S Boss
H Glen
J H Beijnen
M Keesen
R Morrison
B Tait
W Copalu
A Mazur
J Wanders
J P O'Brien
J H M Schellens
T R J Evans
机构
[1] The Netherlands Cancer Institute,Division of Medical Oncology, Department of Clinical Pharmacology
[2] Plesmanlaan 121,Department of Pharmacy
[3] Beatson West of Scotland Cancer Centre,Department of Biomedical Analysis
[4] Slotervaart Hospital,undefined
[5] Utrecht University,undefined
[6] Eisai Europe Limited,undefined
[7] European Knowledge Centre,undefined
[8] Eisai Inc.,undefined
[9] Woodcliff Lake,undefined
[10] NJ,undefined
[11] USA,undefined
[12] Institute of Cancer Sciences,undefined
[13] University of Glasgow,undefined
来源
British Journal of Cancer | 2012年 / 106卷
关键词
dose escalation; E7080; pharmacokinetics; phase I; receptor tyrosine kinase inhibitor; solid tumours;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:1598 / 1604
页数:6
相关论文
共 282 条
[21]  
Rolland F(2010)Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarrays Hum Pathol 41 375-124
[22]  
Demkow T(2012)Sunitinib therapy for melanoma patients with KIT mutations Clin Cancer Res 18 1457-6476
[23]  
Hutson TE(2007)Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 115-21
[24]  
Gore M(1999)Basic fibroblast growth factor induces a transformed phenotype in normal human melanocytes Oncogene 18 6469-1234
[25]  
Freeman S(2010)A phase II trial of sorafenib in metastatic melanoma with tissue correlates PLoS One 5 e15588-143
[26]  
Schwartz B(2004)Inhibition of proliferation and survival of melanoma cells by adenoviral-mediated expression of dominant negative fibroblast growth factor receptor Melanoma Res 14 13-2887
[27]  
Shan M(2009)Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil J Clin Oncol 27 1227-1778
[28]  
Simantov R(2008)The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway Curr Clin Pharmacol 3 132-556
[29]  
Bukowski RM(2006)Biology of vascular endothelial growth factors FEBS Lett 580 2879-216
[30]  
Eskens FA(1990)Purification and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor Cancer Res 50 1774-13